References
1. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the
Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a
Report of 72314 Cases From the Chinese Center for Disease Control and
Prevention. JAMA 2020.
2. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli
A, Cereda D, Coluccello A, Foti G, Fumagalli R, Iotti G, Latronico N,
Lorini L, Merler S, Natalini G, Piatti A, Ranieri MV, Scandroglio AM,
Storti E, Cecconi M, Pesenti A, Network C-LI, Nailescu A, Corona A,
Zangrillo A, Protti A, Albertin A, Forastieri Molinari A, Lombardo A,
Pezzi A, Benini A, Scandroglio AM, Malara A, Castelli A, Coluccello A,
Micucci A, Pesenti A, Sala A, Alborghetti A, Antonini B, Capra C,
Troiano C, Roscitano C, Radrizzani D, Chiumello D, Coppini D, Guzzon D,
Costantini E, Malpetti E, Zoia E, Catena E, Agosteo E, Barbara E,
Beretta E, Boselli E, Storti E, Harizay F, Della Mura F, Lorini FL,
Donato Sigurta F, Marino F, Mojoli F, Rasulo F, Grasselli G, Casella G,
De Filippi G, Castelli G, Aldegheri G, Gallioli G, Lotti G, Albano G,
Landoni G, Marino G, Vitale G, Battista Perego G, Evasi G, Citerio G,
Foti G, Natalini G, Merli G, Sforzini I, Bianciardi L, Carnevale L,
Grazioli L, Cabrini L, Guatteri L, Salvi L, Dei Poli M, Galletti M,
Gemma M, Ranucci M, Riccio M, Borelli M, Zambon M, Subert M, Cecconi M,
Mazzoni MG, Raimondi M, Panigada M, Belliato M, Bronzini N, Latronico N,
Petrucci N, Belgiorno N, Tagliabue P, Cortellazzi P, Gnesin P, Grosso P,
Gritti P, Perazzo P, Severgnini P, Ruggeri P, Sebastiano P, Covello RD,
Fernandez-Olmos R, Fumagalli R, Keim R, Rona R, Valsecchi R, Cattaneo S,
Colombo S, Cirri S, Bonazzi S, Greco S, Muttini S, Langer T, Alaimo V,
Viola U. Baseline Characteristics and Outcomes of 1591 Patients Infected
With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA
2020.
3. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X,
Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D,
Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk Factors
Associated With Acute Respiratory Distress Syndrome and Death in
Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA
Intern Med 2020.
4. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z,
Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138
Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in
Wuhan, China. JAMA 2020.
5. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T,
Davidson KW, the Northwell C-RC, Barnaby DP, Becker LB, Chelico JD,
Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello AJ,
Duer-Hefele J, Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk
DA, Kim EJ, Kozel ZM, Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos
TP. Presenting Characteristics, Comorbidities, and Outcomes Among 5700
Patients Hospitalized With COVID-19 in the New York City Area. JAMA
2020; 323: 2052-59.
6. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak
Y, Tobin KA, Cerfolio RJ, Francois F, Horwitz LI. Factors associated
with hospital admission and critical illness among 5279 people with
coronavirus disease 2019 in New York City: prospective cohort study. BMJ
2020; 369: m1966.
7. van Haren FMP, Page C, Laffey JG, Artigas A, Camprubi-Rimblas M,
Nunes Q, Smith R, Shute J, Carroll M, Tree J, Carroll M, Singh D,
Wilkinson T, Dixon B. Nebulised heparin as a treatment for COVID-19:
scientific rationale and a call for randomised evidence. Crit Care 2020;
24: 454.
8. Conzelmann C, Muller JA, Perkhofer L, Sparrer KM, Zelikin AN, Munch
J, Kleger A. Inhaled and systemic heparin as a repurposed direct
antiviral drug for prevention and treatment of COVID-19. Clin Med (Lond)
2020.
9. Mycroft-West C, Su D, Elli S, Guimond S, Miller G, Turnbull J, Yates
E, Guerrini M, Fernig D, Lima M, Skidmore M. The 2019 coronavirus
(SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain
undergoes conformational change upon heparin binding. bioRxiv 2020.
10. Kwon PS, Oh H, Kwon SJ, Jin W, Zhang F, Fraser K, Hong JJ, Linhardt
RJ, Dordick JS. Sulfated polysaccharides effectively inhibit SARS-CoV-2
in vitro. Cell Discov 2020; 6: 50.
11. Clausen TM, Sandoval DR, Spliid CB, Pihl J, Perrett HR, Painter CD,
Narayanan A, Majowicz SA, Kwong EM, McVicar RN, Thacker BE, Glass CA,
Yang Z, Torres JL, Golden GJ, Bartels PL, Porell RN, Garretson AF,
Laubach L, Feldman J, Yin X, Pu Y, Hauser BM, Caradonna TM, Kellman BP,
Martino C, Gordts P, Chanda SK, Schmidt AG, Godula K, Leibel SL, Jose J,
Corbett KD, Ward AB, Carlin AF, Esko JD. SARS-CoV-2 Infection Depends on
Cellular Heparan Sulfate and ACE2. Cell 2020; 183: 1043-57 e15.
12. Tree JA, Turnbull JE, Buttigieg KR, Elmore MJ, Coombes N, Hogwood J,
Mycroft-West CJ, Lima MA, Skidmore MA, Karlsson R, Chen YH, Zhang Y,
Spalluto CM, Staples KJ, Yates EA, Gray E, Singh D, Wilkinson T, Page
CP, Carroll MW. Unfractionated heparin inhibits live wild-type
SARS-CoV-2 cell infectivity at therapeutically relevant concentrations.
Br J Pharmacol 2020.
13. Dixon B, Schultz MJ, Hofstra JJ, Campbell DJ, Santamaria JD.
Nebulized heparin reduces levels of pulmonary coagulation activation in
acute lung injury. Crit Care 2010; 14: 445.
14. Dixon B, Campbell DJ, Santamaria JD. Elevated pulmonary dead space
and coagulation abnormalities suggest lung microvascular thrombosis in
patients undergoing cardiac surgery. Intensive Care Medicine 2008; 34:
1216-23.
15. Dixon B, Schultz MJ, Smith R, Fink JB, Santamaria JD, Campbell DJ.
Nebulized heparin is associated with fewer days of mechanical
ventilation in critically ill patients: a randomized controlled trial.
Crit care 2010; 14: R180.
16. Dixon B, Smith R, Santamaria JD, Orford NR, Wakefield BJ, Ives K,
McKenzie R, Zhang B, Yap CH. A trial of nebulised heparin to limit lung
injury following cardiac surgery. Anaesth Intensive Care 2016; 44:
28-33.
17. Dixon B, Smith R. Nebulised Heparin for Lung Injury - Clinical
Protocol V1. In: St.Vincent’s Hospital Melbourne Australia, 2011.
18. Dixon B, Smith R, Campbell D, Moran J, Doig G, Rechnitzer T,
MacIsaac C, Simpson N, van Haren F, Ghosh A, Gupta S, Broadfield E,
Crozier T, French C, Santamaria J. Nebulised heparin for patients with
or at risk of acute respiratory distress syndrome: a multicentre,
randomised, double-blind, placebo-controlled phase 3 trial. Lancet
Respir Med [accepted for publication 05 October 2020; in-press].
19. Petkova E, Antman EM, Troxel AB. Pooling Data From Individual
Clinical Trials in the COVID-19 Era. JAMA 2020.
20. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC,
Krleza-Jeric K, Hrobjartsson A, Mann H, Dickersin K, Berlin JA, Dore CJ,
Parulekar WR, Summerskill WS, Groves T, Schulz KF, Sox HC, Rockhold FW,
Rennie D, Moher D. SPIRIT 2013 statement: defining standard protocol
items for clinical trials. Ann Intern Med 2013; 158: 200-7.
21. Li J, Pavlov I, Laffey JG, Roca O, Mirza S, Perez Y, McNicholas B,
Cosgrave D, Vines D, Tavernier E, Ehrmann S. Meta-trial of awake prone
positioning with nasal high flow therapy: Invitation to join a pandemic
collaborative research effort. J Crit Care 2020; 60: 140-42.
22. Characterisation WHOWGotC, Management of C-i. A minimal common
outcome measure set for COVID-19 clinical research. Lancet Infect Dis
2020; 20: e192-e97.
23. Lewis RJ, Angus DC. Time for Clinicians to Embrace Their Inner
Bayesian?: Reanalysis of Results of a Clinical Trial of Extracorporeal
Membrane Oxygenation. JAMA 2018; 320: 2208-10.
24. Saville BR, Connor JT, Ayers GD, Alvarez J. The utility of Bayesian
predictive probabilities for interim monitoring of clinical trials. Clin
Trials 2014; 11: 485-93.